DeepMed Research

Defactinib

Generic Name: Defactinib

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁F_₃N_₈O_₃S

CAS Number: 1073154-85-4

Unique Ingredient Identifier: 53O87HA2QU

Background: Defactinib has been investigated for the treatment of Malignant Pleural Mesothelioma.

Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Bladder Carcinoma
Breast Carcinoma
Cervical Carcinoma
Colon Carcinoma
Colorectal Carcinoma
Endometrial Carcinoma
Esophageal Carcinoma
Exocrine Pancreas Carcinoma

Interventions: Drug: Afatinib
Drug: Capivasertib
Drug: Binimetinib
Drug: Adavosertib
Drug: Afatinib Dimaleate
Drug: Dabrafenib
Drug: Defactinib
Drug: Fexagratinib
Drug: Dasatinib
Drug: Ipatasertib
Procedure: Biopsy Procedure
Drug: Crizotinib
Drug: Dabrafenib Mesylate
Drug: Taselisib
Drug: Sapanisertib
Drug: PI3K-beta Inhibitor GSK2636771
Drug: Defactinib Hydrochloride
Biological: Nivolumab
Drug: Palbociclib
Drug: Copanlisib
Drug: Ulixertinib
Procedure: Biospecimen Collection
Biological: Trastuzumab Emtansine
Drug: Copanlisib Hydrochloride
Biological: Relatlimab
Procedure: Computed Tomography
Drug: Trametinib
Biological: Pertuzumab
Drug: Erdafitinib
Other: Cytology Specimen Collection Procedure
Procedure: Radiologic Examination
Procedure: Multigated Acquisition Scan
Drug: Larotrectinib
Procedure: Echocardiography Test
Drug: Osimertinib
Biological: Trastuzumab
Drug: Larotrectinib Sulfate
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Vismodegib
Drug: Sunitinib Malate
Procedure: Radionuclide Imaging

First Posted Date: 2015-06-08

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6452

Registration Number: NCT02465060

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Thomas Hospital, Fairhope, Alabama, United States
🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States

and more 1406 locations

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

Phase 2

Terminated

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: VS-6063

First Posted Date: 2013-12-06

Last Posted Date: 2024-02-20

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 35

Registration Number: NCT02004028

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: defactinib (VS-6063)

First Posted Date: 2013-09-27

Last Posted Date: 2017-04-13

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 55

Registration Number: NCT01951690

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
University of Colorado Cancer Center, Anschutz Medical Campus, Denver, Colorado, United States

and more 6 locations

Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies

Phase 1

Completed

Conditions: Non Hematologic Cancers

Interventions: Drug: Defactinib

First Posted Date: 2013-09-16

Last Posted Date: 2017-03-09

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 9

Registration Number: NCT01943292

Locations: 🇯🇵
Kinki University Hospital, Osaka, Japan

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

Phase 2

Terminated

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: Placebo
Drug: defactinib (VS-6063)

First Posted Date: 2013-06-06

Last Posted Date: 2017-01-30

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 344

Registration Number: NCT01870609

Locations: 🇺🇸
University of California San Francisco Medical Center, San Francisco, California, United States
🇫🇷
Gustave Roussy, Villejuif, France
🇬🇧
Royal Surrey County Hospital, Guildford, United Kingdom

and more 70 locations

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: defactinib
Drug: Paclitaxel

First Posted Date: 2013-01-29

Last Posted Date: 2017-05-17

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 22

Registration Number: NCT01778803

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States

A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: PF-04554878

First Posted Date: 2008-11-07

Last Posted Date: 2017-01-25

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 46

Registration Number: NCT00787033

Locations: 🇨🇦
Pfizer Investigational Site, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy